Skip to main content

Table 1 Biochemical findings

From: Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model

Treatment Liver function biomarkers Kidney function biomarkers
AST (Unit/L) ALT (Unit/L) Bilirubin (mg/dl) BUN (mg/dl) Creatinine (mg/dl)
PBS 168 ± 63.3 67 ± 27.5 0.1 27.0 ± 1.7 0.21 ± 0.02
Ad-ΔB 190 ± 36.4 52 ± 17.8 0.1 29.3 ± 5.5 0.20 ± 0.01
Ad-ΔB/TRAIL + Ad-ΔB/IL-12 118 ± 12.5 52 ± 42.2 0.2 30.6. ± 2.1 0.21 ± 0.02
  1. HCC-bearing mice were systemically treated with PBS, controlled non-armed Ad-ΔB, or combination of Ad-ΔB/TRAIL+Ad-ΔB/IL-12; at a dosage regimen of 1 × 1010 VP/intravenous injection; three times every other day. 72 h after the last dose, serum levels of hepato-renal function biomarkers of each group were assessed. Data are represented as mean ± SE